CAS 70-51-9

Deferoxamina

Descripción:

Deferoxamina es un agente quelante utilizado principalmente en el tratamiento de condiciones de sobrecarga de hierro, como las que resultan de transfusiones de sangre repetidas en pacientes con condiciones como la talasemia o la enfermedad de células falciformes. Es un ligando hexadentado, lo que significa que puede formar múltiples enlaces con un solo ion metálico, uniendo específicamente iones férricos (Fe³⁺) para facilitar su excreción del cuerpo. Deferoxamina se administra típicamente por vías subcutáneas o intravenosas, ya que se absorbe mal del tracto gastrointestinal. El compuesto se caracteriza por su capacidad para formar complejos estables con el hierro, lo que ayuda a reducir la toxicidad del hierro y prevenir daños en los órganos. Además de sus usos terapéuticos, se ha estudiado Deferoxamina por sus posibles propiedades antioxidantes y su papel en diversas aplicaciones de investigación. Su estructura química incluye un grupo funcional ácido hidroxámico, que es crucial para sus propiedades de quelación. En general, Deferoxamina desempeña un papel vital en el manejo de la sobrecarga de hierro y en la mejora de los resultados de los pacientes en trastornos hematológicos específicos.

Fórmula: C₂₅H₄₈N₆O₈

InChI: InChI=1/C25H48N6O8/c1-21(32)29(37)18-9-3-6-16-27-22(33)12-14-25(36)31(39)20-10-4-7-17-28-23(34)11-13-24(35)30(38)19-8-2-5-15-26/h37-39H,2-20,26H2,1H3,(H,27,33)(H,28,34)

Clave InChI: InChIKey=UBQYURCVBFRUQT-UHFFFAOYSA-N

SMILES: C(CCC(NCCCCCN(C(C)=O)O)=O)(N(CCCCCNC(CCC(N(CCCCCN)O)=O)=O)O)=O

Sinónimos:

• 3,9,14,20,25-Pentaazatriacontane-2,10,13,21,24-pentone, 30-amino-3,14,25-trihydroxy-
• 30-Amino-3,14,25-trihydroxy-3,9,14,20,25 pentaazatriacontane-2,10,13,21,24-pentaone
• Butanediamide, N'-[5-[[4-[[5-(acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N-(5-aminopentyl)-N-hydroxy-
• Butanediamide, N⁴-[5-[[4-[[5-(acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N¹-(5-aminopentyl)-N¹-hydroxy-
• Deferoxamin
• Deferoxamina
• Deferoxamine B
• Deferriferrioxamine B
• Deferrioxamine
• Deferrioxamine B
• Desferan
• Desferex
• Desferin
• Desferioxamine B
• Desferoxime
• Desferrin
• Desferrioxamine
• Desferrioxamine B
• Dfo-B
• N'-{5-[acetyl(hydroxy)amino]pentyl}-N-[5-({4-[(5-aminopentyl)(hydroxy)amino]-4-oxobutanoyl}amino)pentyl]-N-hydroxybutanediamide
• N-[5-[3-[(5-Aminopentyl)hydroxycarbamoyl]propionamido]pentyl]-3-[[5-(N-hydroxyacetamido)pentyl]carbamoyl]propionohydroxamic acid
• N⁴-[5-[[4-[[5-(Acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N¹-(5-aminopentyl)-N¹-hydroxybutanediamide
• Nsc 527604
• N′-[5-[Acetyl(hydroxy)amino]pentyl]-N-7-[5-([4-[(5-aminopentyl)(hydroxy)amino]-4-oxobutanoyl]amino)pentyl]-N-hydroxysuccinamide
• Propionohydroxamic acid, N-[5-[3-[(5-aminopentyl)hydroxycarbamoyl]propionamido]pentyl]-3-[[5-(N-hydroxyacetamido)pentyl]carbamoyl]-
• N4-[5-[[4-[[5-(Acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N1-(5-aminopentyl)-N1-hydroxybutanediamide
• Butanediamide, N4-[5-[[4-[[5-(acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N1-(5-aminopentyl)-N1-hydroxy-
• n-[5-[3-[(5-aminopentyl)hydroxycarbamoyl]propionamido]pentyl]-3-[[5-(n-hydroxy
• ba-33112
• deferoxaminum
• n’-[5-[[4-[[5-(acetylhydroxamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pen
• N1-(5-aminopentyl)-N1-hydroxy-N4-(5-(N-hydroxy-4-((5-(N-hydroxyacetamido)pentyl)amino)-4-oxobutanamido)pentyl)succinamide
• butanediamide,n’-(5-((4-((5-(acetylhydroxyamino)pentyl)amino)-1,4-dioxobutyl)h
• deferoxamideb
• entaone
• 1-amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(n-acetylhydroxylamino)-6,11,17,
• acetamido)pentyl]carbamoyl]propionohydroxamicacid
• N'-[5-[acetyl(hydroxy)amino]pentyl]-N-[5-[[4-[5-aminopentyl(hydroxy)amino]-4-keto-butanoyl]amino]pentyl]-N-hydroxy-succinamide
• n-benzoyl-ferrioxamine
• Deferoxamine USP/EP/BP
• taone
• 3,9,14,20,25-pentaazatriacontane-2,10,13,21,24-pentone,30-amino-3,14,25-trihyd
• N1-(5-Aminopentyl)-N1-hydroxy-N4-(5-(N-hydroxy-4-((5-(N-hydroxyacetamido)-pentyl)amino)-4-oxobuta
• deferoxamine
• deferoxamineb
• desferrioxamineb
• 3,9,14,20,25-pentaazatriacontane-2,10,13,21,24-pentone,30-amino-3,14,25-trih
• ba-29837
• tyl]-n-(5-aminopentyl)-n-hydroxybutanediamide
• deferrioxamineb
• desferriferrioxaminb
• 30-amino-3,14,25-trihydroxy-3,9,14,20,25-pentaazatriacontane-2,10,13,21,24-p
• 30-amino-3,14,25-trihydroxy-3,9,14,20,25-pentaazatriacontane-2,10,13,21,24-pen
• ba33112
• N'-{5-[ACETYL(HYDROXY)AMINO]PENTYL}-N-[5-({4-[(5-AMINOPENTYL)(HYDROXY)AMINO]-4-OXOBUTANOYL}AMINO)PENTYL]-N-HYDROXYSUCCINAMIDE
• N'-[5-[[4-[[5-(Acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N-(5-aminopentyl)-N-hydroxysuccinamide
• N-[5-[[4-[5-azanylpentyl(hydroxy)amino]-4-oxo-butanoyl]amino]pentyl]-N'-[5-[ethanoyl(hydroxy)amino]pentyl]-N-hydroxy-butanediamide
• 22-tetraazaheptaeicosane
• n-benzoylferrioxamineb
• DESFEROXAMINE
• DESFERROXAMINE
• desferral
• ydroxyamino)pentyl)-n-(5-aminopentyl)-n-hydroxy-
• dfoa

Deferoxamine Mesylate

CAS: 138-14-7, 70-51-9

Fórmula: C₂₅H₄₈N₆O₈·CH₄O₃S

Pureza: >97.0%(T)(HPLC)

Forma y color: White to Light yellow powder to crystal

Peso molecular: 656.79

Ref: 3B-D4245

Deferoxamine

CAS: 70-51-9

Deferoxamine (Desferrioxamine B) is an iron chelator. Deferoxamine has antioxidant, anti-proliferative and anti-tumor activities. High-Quality, Low-Cost!

Fórmula: C₂₅H₄₈N₆O₈

Pureza: 99.66% - 99.97%

Forma y color: Solid

Peso molecular: 560.68

Ref: TM-T124358

N1-(5-Aminopentyl)-N1-hydroxy-N4-(5-(N-hydroxy-4-((5-(N-hydroxyacetamido)pentyl)amino)-4-oxobutanamido)pentyl)succinamide

CAS: 70-51-9

Fórmula: C₂₅H₄₈N₆O₈

Pureza: 98%

Forma y color: Solid

Peso molecular: 560.6840

Ref: IN-DA005IGL

Deferoxamine

CAS: 70-51-9

Deferoxamine

Pureza: ≥98%

Peso molecular: 560.68g/mol

Ref: 54-BUP04137

Deferoxamine

CAS: 70-51-9

Deferoxamine is a polymerase chain inhibitor that binds to the folate receptor, a protein on the surface of cells. It is used as an antidote to poisoning by iron, arsenic, and other metals. Deferoxamine also has antioxidant properties and can be used in the treatment of iron overload diseases such as hemochromatosis. Deferoxamine-iron complexes are excreted in the urine, which may be useful for monitoring iron homeostasis. This drug is not active against squamous cell carcinomas or wild-type strains of bacteria that do not have a functional folate receptor.

Fórmula: C₂₅H₄₈N₆O₈

Pureza: Min. 95%

Forma y color: Solid

Peso molecular: 560.68 g/mol

Ref: 3D-FD46531